Caribou Biosciences, Inc. has received clearance from the FDA for its investigational new drug application for CB-010, an anti-CD19 CAR-T cell therapy for the treatment of lupus nephritis and extrarenal lupus, and plans to initiate a phase 1 clinical trial by year-end 2024.